Phase 2 Clinical Trial to Evaluate Efficacy and Safety of SM-88 Used With Methoxsalen, Phenytoin, and Sirolimus (MPS) as Maintenance Therapy Following Standard Treatments for Ewing's Sarcoma or as Salvage Therapy for Advanced Sarcomas

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Racemetyrosine (Primary) ; Methoxsalen; Phenytoin; Sirolimus
Indications Ewing's sarcoma; Haemangiosarcoma; Leiomyosarcoma; Sarcoma
Focus Therapeutic Use
Acronyms HopES

Most Recent Events

24 Feb 2025 Planned End Date changed from 31 Mar 2025 to 31 Mar 2028.
24 Feb 2025 Planned primary completion date changed from 19 Dec 2024 to 19 Dec 2027.
16 Apr 2024 Planned End Date changed from 31 Oct 2023 to 31 Mar 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight